Anastrozole: one option of several
135 studies: a test or a strategy chooses among drugs. Page 2 of 2. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1How we knowReport a problem
- Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2How we knowReport a problem
- Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1How we knowReport a problem
- Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled StudyStatus unknownNCT04012918Phase 2How we knowReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWithdrawnNCT03988114Phase 4How we knowReport a problem
- A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03966898Phase 3How we knowReport a problem
- FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerActive, not recruitingNCT03944434Phase 2How we knowReport a problem
- Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCStatus unknownNCT03910712Phase 2How we knowReport a problem
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3How we knowReport a problem
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive, not recruitingNCT03701334Phase 3How we knowReport a problem
- Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2How we knowReport a problem
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedNCT03554044Phase 1How we knowReport a problem
- A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerCompletedNCT03481998Phase 1/2How we knowReport a problem
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingNCT03425838Phase 3How we knowReport a problem
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedNCT03220178Phase 4How we knowReport a problem
- Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2How we knowReport a problem
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3How we knowReport a problem
- Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast CancerStatus unknownNCT02910050Phase 2How we knowReport a problem
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2How we knowReport a problem
- Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerCompletedNCT02767661Phase 3How we knowReport a problem
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced DiseaseTerminatedNCT02730091Phase 3How we knowReport a problem
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerStatus unknownNCT02689921Phase 2How we knowReport a problem
- Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsActive, not recruitingNCT02592083Phase 2How we knowReport a problem
- To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCompletedNCT02549430Phase 2How we knowReport a problem
- Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCompletedNCT02511639Phase 3How we knowReport a problem
- Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2How we knowReport a problem
- DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsCompletedNCT01619111Phase 3How we knowReport a problem
- Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCompletedNCT01553903Phase 4How we knowReport a problem
- Pharmacology of Adjuvant Hormonotherapy in Breast CancerCompletedNCT01127295Phase 4How we knowReport a problem
- Adherence to Oral Anticancer Treatment Using Electronic Monitoring SystemCompletedNCT01058044Not applicableHow we knowReport a problem
- Dendritic Cell Based Therapy for Breast Cancer PatientsWithdrawnNCT00935558Phase 2How we knowReport a problem
- Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast CancerTerminatedNCT00684216Phase 2/3How we knowReport a problem
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast CancerCompletedNCT00508586Phase 1How we knowReport a problem
- Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical TrialCompletedNCT00354302Phase 3How we knowReport a problem
- Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCISWithdrawnNCT00324714Phase 3How we knowReport a problem